Journal
BRAIN RESEARCH BULLETIN
Volume 52, Issue 3, Pages 213-216Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0361-9230(00)00258-6
Keywords
NMDA receptors; phencyclidine; schizophrenia; mouse
Categories
Funding
- NIDA NIH HHS [DA03383] Funding Source: Medline
- NIMH NIH HHS [MH01439] Funding Source: Medline
Ask authors/readers for more resources
Phencyclidine (PCP) and other N-methyl-D-aspartate (NMDA) antagonists induce schizophrenia-like symptoms in humans. In rodents, PCP induces a syndrome of stereotypies and hyperactivity that is accompanied by stimulation of striatal dopamine release. Glycine and other NMDA agonists reverse PCP-induced behaviors in rodents and ameliorate PCP psychosis-like symptoms of schizophrenia in clinical trials. Glycine levels in vivo are regulated by the actions of glycine (GLYT1) transporters. The present study investigates effects of glycine and the prototypic glycine transport inhibitor glycyldodecylamide (GDA) on striatal dopamine release in vitro using a mouse striatal assay. Glycine and GDA significantly inhibit NMDA-induced striatal dopamine release, consistent with their ability to enhance local striatal inhibitory neurotransmission in vitro and to reverse PCP-induced hyperactivity in vivo. (C) 2000 Elsevier Science inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available